Search

Your search keyword '"Vigliotti, Maria Luigia"' showing total 10 results
Start Over Author "Vigliotti, Maria Luigia" Search Limiters Available in Library Collection
10 results on '"Vigliotti, Maria Luigia"'

3. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

Author

D’Arena, Giovanni, Simeon, Vittorio, Laurenti, Luca, Cimminiello, Michele, Innocenti, Idanna, Gilio, Michele, Padula, Angela, Vigliotti, Maria Luigia, De Lorenzo, Sonya, Loseto, Giacomo, Passarelli, Anna, Di Minno, Matteo Nicola Dario, Tucci, Marco, De Feo, Vincenzo, D'Auria, Fiorella, Silvestris, Francesco, Di Minno, Giovanni, Musto, Pellegrino, Laurenti, Luca (ORCID:0000-0002-8327-1396), D’Auria, Fiorella, D’Arena, Giovanni, Simeon, Vittorio, Laurenti, Luca, Cimminiello, Michele, Innocenti, Idanna, Gilio, Michele, Padula, Angela, Vigliotti, Maria Luigia, De Lorenzo, Sonya, Loseto, Giacomo, Passarelli, Anna, Di Minno, Matteo Nicola Dario, Tucci, Marco, De Feo, Vincenzo, D'Auria, Fiorella, Silvestris, Francesco, Di Minno, Giovanni, Musto, Pellegrino, Laurenti, Luca (ORCID:0000-0002-8327-1396), and D’Auria, Fiorella

Abstract

Rituximab is an effective treatment for CD20 + B-cell malignancies and autoimmune disorders. However, adverse drug reactions (ADRs) may occur after rituximab infusion, causing, in rare cases, its discontinuation. In this multicenter, retrospective study, among 374 patients treated with rituximab i.v., 23.5% experienced ADRs. Mean follow-up was 20.6 months (range 8–135). Overall, ADRs were significantly more frequent in non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemias (25–35.9%), than in autoimmune diseases (9.4–17.5%) (p <.0001). Grade 3–4 toxicity was observed in eight patients (2.1%), and in four of them (1% of all patients) definitive drug discontinuation was necessary. Interestingly, three groups of patients with different risk of developing ADR were identified, according to a predictive heat-map developed combining four parameters (splenomegaly, history of allergy, hemoglobin levels and gender) selected by multivariate analysis. This model may be useful in identifying patients at higher risk of ADRs, needing appropriate preventing therapies.

Published
2017

7. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia

Author

D'Arena, Giovanni, primary, Laurenti, Luca, additional, Capalbo, Silvana, additional, D'Arco, Alfonso Maria, additional, De Filippi, Rosaria, additional, Marcacci, Gianpaolo, additional, Di Renzo, Nicola, additional, Storti, Sergio, additional, Califano, Catello, additional, Vigliotti, Maria Luigia, additional, Tarnani, Michela, additional, Ferrara, Felicetto, additional, and Pinto, Antonio, additional

Published
2006
Full Text
View/download PDF

10. CD38 expression does not change in B-cell chronic lymphocytic leukemia

Author

D'Arena, Giovanni, primary, Nunziata, Giuseppe, additional, Coppola, Giuseppe, additional, Vigliotti, Maria Luigia, additional, Tartarone, Alfredo, additional, Carpinelli, Nicola, additional, Matera, Rosella, additional, Bisogno, Rosario Colella, additional, Pistolese, Giuseppe, additional, and Di Renzo, Nicola, additional

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results